{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:14:55Z","timestamp":1790180095645,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003474.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T00:00:00Z","timestamp":1509321600000}}],"reference-count":252,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003474.pub4","type":"journal-article","created":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T02:53:05Z","timestamp":1509331985000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Bisphosphonates and other bone agents for breast cancer"],"prefix":"10.1002","volume":"2018","author":[{"given":"Brent","family":"O'Carrigan","sequence":"first","affiliation":[{"name":"Chris O'Brien Lifehouse; Medical Oncology; 119-143 Missenden Rd Camperdown Sydney NSW UK 2050"},{"name":"The University of Sydney; Camperdown Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew HF","family":"Wong","sequence":"additional","affiliation":[{"name":"Gosford Hospital; Department of Medical Oncology; Gosford New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina L","family":"Willson","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, The University of Sydney; Systematic Reviews and Health Technology Assessments; Locked Bag 77 Sydney NSW Australia 1450"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R","family":"Stockler","sequence":"additional","affiliation":[{"name":"The University of Sydney; NHMRC Clinical Trials Centre and Sydney Cancer Centre; GH6 RPAH Missenden Road Camperdown NSW Australia 2050"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[{"name":"Royal North Shore Hospital; Department of Medical Oncology; Pacific Highway St Leonards New South Wales Australia 2065"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"Goodwin","sequence":"additional","affiliation":[{"name":"The University of Sydney, Concord Repatriation General Hospital; Concord Clinical School; Concord NSW Australia 2137"},{"name":"Concord Repatriation General Hospital; Medical Oncology Department; Concord Australia"},{"name":"Sydney Local Health District and South Western Sydney Local Health District; Cancer Genetics Department; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,30]]},"reference":[{"key":"10.1002\/14651858.CD003474.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1158\/0008-5472.SABCS11-S1-2","article-title":"Long-term follow-up in ABCSG-12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor-positive early breast cancer","volume":"71","author":"Gnant","year":"2011","journal-title":"Cancer Research"},{"issue":"7","key":"10.1002\/14651858.CD003474.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD003474.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"Gnant M Mlineritsch B Stoeger H Luschin-Ebengreuth G Knauer M Moik M Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12 Annals of Oncology 2015 313 20","DOI":"10.1093\/annonc\/mdu544"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1200\/jco.2010.28.15_suppl.533","article-title":"Mature results from ABCSG-12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer","volume":"28","author":"Gnant","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"9992","key":"10.1002\/14651858.CD003474.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"433-43","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/jco.2015.33.15_suppl.504","article-title":"Adjuvant denosumab in breast cancer: results from 3,425 post-menopausal patients of the ABCSG18 trial","volume":"33","author":"Gnant","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0008|cit8","first-page":"S2","article-title":"The impact of adjuvant denosumab on disease-free survival: results from 3,425 postmenopausal patients of the ABCSG-18 trial","volume":"76","author":"Gnant","year":"2016","journal-title":"Cancer Research"},{"issue":"5","key":"10.1002\/14651858.CD003474.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","article-title":"Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial","volume":"11","author":"Aft","year":"2010","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD003474.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/bjc.2012.210","article-title":"Effect of (neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II\/III breast cancer","volume":"107","author":"Aft","year":"2012","journal-title":"British Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD003474.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD003474.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD003474.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"issue":"3","key":"10.1002\/14651858.CD003474.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo-controlled trial","volume":"17","author":"Theriault","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD003474.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","article-title":"Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial","volume":"15","author":"Coleman","year":"2014","journal-title":"Lancet Oncology"},{"issue":"2","key":"10.1002\/14651858.CD003474.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-011-1429-y","article-title":"Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II\/III breast cancer","volume":"127","author":"Coleman","year":"2011","journal-title":"Breast Cancer Research and Treatment"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0017|cit17","first-page":"P2","article-title":"Impact of zoledronic acid on fractures, bone mineral density and bone remodeling in the AZURE trial (BIG 01-04)","volume":"71","author":"Coleman","year":"2011","journal-title":"Cancer Research"},{"issue":"15","key":"10.1002\/14651858.CD003474.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0019|cit19","first-page":"S6","article-title":"Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study","volume":"72","author":"Coleman","year":"2012","journal-title":"Cancer Research"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0020|cit20","first-page":"S4","article-title":"Adjuvant treatment with zoledronic acid in stage II\/III breast cancer. The AZURE trial (BIG 01\/04)","volume":"70","author":"Coleman","year":"2010","journal-title":"Cancer Research"},{"issue":"7","key":"10.1002\/14651858.CD003474.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","article-title":"The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer","volume":"102","author":"Coleman","year":"2010","journal-title":"British Journal of Cancer"},{"issue":"21","key":"10.1002\/14651858.CD003474.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1200\/JCO.2012.46.4792","article-title":"Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01\/04)","volume":"31","author":"Rathbone","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD003474.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0024|cit24","unstructured":"Body JJ Lichinitser MR Diehl I Schlosser K Pfarr E Cavalli F Double-blind placebo-controlled trial of intravenous ibandronate in breast cancer metastatic to bone Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago Chicago American Society of Clinical Oncology 1999 575a"},{"issue":"11","key":"10.1002\/14651858.CD003474.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.ejca.2004.03.025","article-title":"Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer","volume":"40","author":"Diel","year":"2004","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0026|cit26","unstructured":"Lyubimova N Kushlinksky NE Lichinitser MR Long-term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003 New York Supportive Care in Cancer 2003"},{"issue":"3","key":"10.1002\/14651858.CD003474.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"issue":"6","key":"10.1002\/14651858.CD003474.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0029|cit29","doi-asserted-by":"crossref","unstructured":"Himelstein AL Qin R Novotny PJ Seisler DK Khatcheressian JL Roberts JD CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer Journal of Clinical Oncology 2015 9501","DOI":"10.1200\/jco.2015.33.15_suppl.9501"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0030|cit30","unstructured":"NCT00869206 Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement clinicaltrials.gov\/ct2\/show\/NCT00869206"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD003474.pub4-BIB0031|cit31","first-page":"41","article-title":"Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial","volume":"5","author":"Conte","year":"1994","journal-title":"Annals of Oncology"},{"issue":"9","key":"10.1002\/14651858.CD003474.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1200\/JCO.1996.14.9.2552","article-title":"Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial","volume":"14","author":"Conte","year":"1996","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD003474.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD003474.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","article-title":"Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up","volume":"19","author":"Diel","year":"2008","journal-title":"Annals of Oncology"},{"issue":"14 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1200\/jco.2004.22.90140.529","article-title":"Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow: a long-term follow-up","volume":"22","author":"Jaschke","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0036|cit36","unstructured":"Diel IJ Marschner N Kindler M Lange O Untach M Hurtz HJ Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488) Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago Chicago American Society of Clinical Oncology 1999"},{"issue":"8317","key":"10.1002\/14651858.CD003474.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0140-6736(83)92755-1","article-title":"Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases","volume":"1","author":"Elomaa","year":"1983","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD003474.pub4-BIB0038|cit38","first-page":"111","article-title":"Clodronate for osteolytic metastases due to breast cancer","volume":"42","author":"Elomaa","year":"1988","journal-title":"Biomedicine and Pharmacotherapy"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003474.pub4-BIB0039|cit39","first-page":"53","article-title":"Treatment of skeletal disease in breast cancer: a controlled clodronate trial","volume":"8","author":"Elomma","year":"1987","journal-title":"Bone"},{"issue":"1","key":"10.1002\/14651858.CD003474.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clbc.2011.08.002","article-title":"Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial","volume":"12","author":"Llombart","year":"2012","journal-title":"Clinical Breast Cancer"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0041|cit41","unstructured":"Llombarto A Frassoldati A Paija O Sleeboom HP Jerusalem G Mebis J Effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow-up ASCO Breast Cancer Symposium; 2009; Chicago Chicago American Society of Clinical Oncology 2009"},{"issue":"10","key":"10.1002\/14651858.CD003474.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"18 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.1200\/jco.2006.24.18_suppl.8562","article-title":"A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption","volume":"24","author":"Suarez","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0045|cit44","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1200\/jco.2014.32.15_suppl.1009","article-title":"German Adjuvant Intergroup Node Positive (GAIN) study: a phase III trial to compare IDD-ETC versus EC-TX in patients with node-positive primary breast cancer-final efficacy analysis","volume":"32","author":"Moebus","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD003474.pub4-BIB0044|cit45","first-page":"S2","article-title":"GAIN study: a phase III trial to compare ETC vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer - 1st interim efficacy analysis","volume":"71","author":"M\u00f6bus","year":"2011","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0046|cit46","unstructured":"NCT00196872 A study to compare ETC vs EC-TX and ibandronate vs observation in patients with node-positive primary breast cancer clinicaltrials.gov\/ct2\/show\/NCT00196872"},{"issue":"28","key":"10.1002\/14651858.CD003474.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1200\/JCO.2012.47.2167","article-title":"German Adjuvant Intergroup Node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer","volume":"31","author":"Minckwitz","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD003474.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1359-6349(05)80728-1","article-title":"Efficacy of ibandronate for the prevention of skeletal-related events in breast cancer patients with metastatic bone disease","volume":"3","author":"Heras","year":"2005","journal-title":"European Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD003474.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2354.2008.00980.x","article-title":"Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer","volume":"18","author":"Heras","year":"2009","journal-title":"European Journal of Cancer Care"},{"issue":"2","key":"10.1002\/14651858.CD003474.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1210\/jc.2009-1366","article-title":"Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment","volume":"95","author":"Hershman","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"29","key":"10.1002\/14651858.CD003474.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1200\/JCO.2008.16.4707","article-title":"Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer","volume":"26","author":"Hershman","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"4C","key":"10.1002\/14651858.CD003474.pub4-BIB0052|cit52","first-page":"3383","article-title":"Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double-blind placebo-controlled multicenter study","volume":"19","author":"Hultborn","year":"1999","journal-title":"Anticancer Research"},{"issue":"6","key":"10.1002\/14651858.CD003474.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S8756-3282(96)00285-2","article-title":"Clodronate decreases the frequency of skeletal metastases in women with breast cancer","volume":"19","author":"Kanis","year":"1996","journal-title":"Bone"},{"issue":"15","key":"10.1002\/14651858.CD003474.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD003474.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2796.1999.00507.x","article-title":"Oral clodronate in breast cancer patients with bone metastases: a randomised study","volume":"246","author":"Kristensen","year":"1999","journal-title":"Journal of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD003474.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1080\/02841860801964988","article-title":"Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer","volume":"47","author":"Kristensen","year":"2008","journal-title":"Acta Oncologica"},{"issue":"20","key":"10.1002\/14651858.CD003474.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1158\/1078-0432.CCR-07-5234","article-title":"Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy","volume":"14","author":"Lipton","year":"2008","journal-title":"Clinical Cancer Research"},{"issue":"28","key":"10.1002\/14651858.CD003474.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003474.pub4-BIB0059|cit59","first-page":"177","article-title":"Adjuvant clodronate therapy in patients with locally advanced breast cancer - long term results of a double blind randomised trial","volume":"47","author":"Mardiak","year":"2000","journal-title":"Neoplasma"},{"issue":"2","key":"10.1002\/14651858.CD003474.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000226904","article-title":"Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton","volume":"48","author":"Martoni","year":"1991","journal-title":"Oncology"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.05.015","article-title":"Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - the phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36\/ABCSG 29)","volume":"64","author":"Minckwitz","year":"2016","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0062|cit62","unstructured":"NCT00512993 Postoperative use of zoledronic acid in breast cancer patients after neoadjuvant chemotherapy (NATAN) clinicaltrials.gov\/ct2\/show\/NCT00512993"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0063|cit63","first-page":"S5","article-title":"Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines-taxane-based chemotherapy for primary breast cancer - the phase III NATAN study (GBG 36\/ABCSG XX)","volume":"73","author":"Minckwitz","year":"2013","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0064|cit64","doi-asserted-by":"crossref","unstructured":"Paterson AH Anderson SJ Lembersky BC Fehrenbacher L Falkson CI King KM Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial Lancet Oncology 2012 734 42","DOI":"10.1016\/S1470-2045(12)70226-7"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0065|cit65","first-page":"S2","article-title":"NSABP protocol B-34: a clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and\/or tamoxifen or no therapy - final analysis","volume":"71","author":"Paterson","year":"2011","journal-title":"Cancer Research"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"LBA9500","DOI":"10.1200\/jco.2014.32.18_suppl.lba9500","article-title":"Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE-2 trial","volume":"32","author":"Hortobagyi","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0067|cit67","unstructured":"NCT00320710 Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer clinicaltrials.gov\/ct2\/show\/NCT00320710"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0068|cit68","unstructured":"Paterson AHG Kanis JA Powles TJ McCloskey EV Archabault WT Kurman MR A re-analysis of a trial of clodronate in patients with breast cancer and bone metastases Anthra Pharmaceuticals"},{"issue":"1","key":"10.1002\/14651858.CD003474.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD003474.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00002018-200326090-00005","article-title":"Extended safety profile of oral clodronate after long-term use in primary breast cancer patients","volume":"26","author":"Atula","year":"2003","journal-title":"Drug Safety"},{"issue":"3","key":"10.1002\/14651858.CD003474.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ejca.2009.12.003","article-title":"Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer","volume":"46","author":"McCloskey","year":"2009","journal-title":"European Journal of Cancer"},{"issue":"14 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/jco.2004.22.90140.528","article-title":"Oral clodronate for the adjuvant treatment of operable breast cancer: results of a randomised, double-blind, placebo-controlled multicenter trial","volume":"22","author":"Powles","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD003474.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Research"},{"issue":"15","key":"10.1002\/14651858.CD003474.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized,\u00a0placebo-controlled\u00a0trial\u00a0of\u00a0clodronate\u00a0in\u00a0patients\u00a0with\u00a0primary\u00a0operable\u00a0breast cancer","volume":"20","author":"Powles","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD003474.pub4-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD003474.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"5","key":"10.1002\/14651858.CD003474.pub4-BIB0077|cit77","first-page":"377","article-title":"Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD003474.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","article-title":"Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5 year results of a randomised controlled study","volume":"19","author":"Saarto","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD003474.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/02841860410032885","article-title":"Ten-year\u00a0follow-up\u00a0of a\u00a0randomized controlled trial\u00a0of\u00a0adjuvant\u00a0clodronate\u00a0treatment\u00a0in\u00a0node-positive\u00a0breast cancer\u00a0patients","volume":"43","author":"Saarto","year":"2004","journal-title":"Acta Oncologica"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"A279","DOI":"10.1016\/S1098-3015(11)72040-X","article-title":"Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases","volume":"13","author":"Body","year":"2010","journal-title":"Value in Health"},{"issue":"4","key":"10.1002\/14651858.CD003474.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.27789","article-title":"Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid","volume":"119","author":"Cleeland","year":"2013","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0082|cit82","first-page":"22","article-title":"A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS)","volume":"18","author":"Boer","year":"2012","journal-title":"Journal of Oncology Pharmacy Practice"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0083|cit83","first-page":"40","article-title":"Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid","volume":"8","author":"Boer","year":"2012","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0084|cit84","first-page":"44","article-title":"Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre-specified two year open-label extension treatment phase of a pivotal phase iii study","volume":"8","author":"Boer","year":"2012","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1016\/S0959-8049(11)71124-8","article-title":"Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease","volume":"47","author":"Diel","year":"2011","journal-title":"European Journal of Cancer"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0086|cit86","first-page":"P4","article-title":"Pain severity and analgesic use associated with skeletal-related events in patients with advanced breast cancer and bone metastases","volume":"71","author":"Fallowfield","year":"2011","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0087|cit87","first-page":"S37","article-title":"Health-related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid","volume":"20","author":"Fallowfield","year":"2012","journal-title":"Supportive Care in Cancer"},{"issue":"27 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/jco.2011.29.27_suppl.272","article-title":"Effect of denosumab versus zoledronic acid on health-related quality of life in patients with metastatic breast cancer","volume":"29","author":"Fallowfield","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/0008-5472.SABCS10-P1-13-05","article-title":"Abstract P1-13-05: The effect of treatment with denosumab or zoledronic acid on health-related quality of life in patients with metastatic breast cancer 262 2631","volume":"70","author":"Fallowfield","year":"2010","journal-title":"Cancer Research"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"9501","DOI":"10.1200\/jco.2014.32.15_suppl.9501","article-title":"Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal-related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics","volume":"32","author":"Lipton","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1158\/1078-0432.CCR-11-3310","article-title":"Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid","volume":"18","author":"Martin","year":"2012","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0092|cit92","first-page":"22","article-title":"Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease","volume":"18","author":"Spencer","year":"2012","journal-title":"Journal of Oncology Pharmacy Practice"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0093|cit93","first-page":"45","article-title":"Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post-hoc analysis of the effect of denosumab treatment","volume":"8","author":"Spencer","year":"2012","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0094|cit94","first-page":"09","article-title":"A comparison of denosumab versus zoledronic acid for the prevention of skeletal-related events in breast cancer patients with bone metastases","volume":"69","author":"Stopeck","year":"2009","journal-title":"Cancer Research"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1200\/jco.2010.28.15_suppl.1024","article-title":"Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial","volume":"28","author":"Stopeck","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0096|cit96","first-page":"P6","article-title":"Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase","volume":"70","author":"Stopeck","year":"2010","journal-title":"Cancer Research"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0097|cit97","first-page":"P3","article-title":"Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2-year open-label extension treatment phase of a pivotal phase 3 study","volume":"71","author":"Stopeck","year":"2011","journal-title":"Cancer Research"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ejca.2012.02.016","article-title":"Results from the 2-year open-label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab","volume":"48","author":"Stopeck","year":"2012","journal-title":"European Journal of Cancer"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0099|cit99","first-page":"P6","article-title":"Abstract P6-14-09: Acute-phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases","volume":"70","author":"Stopeck","year":"2010","journal-title":"Cancer Research"},{"issue":"35","key":"10.1002\/14651858.CD003474.pub4-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1200\/jco.2015.33.15_suppl.503","article-title":"Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG\/Alliance\/ECOG-ACRIN\/NCIC Clinical Trials Group\/NRG Oncology study S0307","volume":"33","author":"Gralow","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/jco.2014.32.15_suppl.558","article-title":"SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient-stated preference for oral versus intravenous delivery","volume":"32","author":"Gralow","year":"2014","journal-title":"Journal of Clinical Oncoloy"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0103|cit103","unstructured":"NCT00127205 Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer clinicaltrials.gov\/ct2\/show\/NCT00127205"},{"issue":"6","key":"10.1002\/14651858.CD003474.pub4-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3816\/CBC.2010.n.062","article-title":"Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer","volume":"10","author":"Leal","year":"2010","journal-title":"Clinical Breast Cancer"},{"issue":"18 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"19558","DOI":"10.1200\/jco.2007.25.18_suppl.19558","article-title":"Randomized trial to assess bone mineral density (BMD) effects of zoledronic acid (ZA) in postmenopausal women (PmW) with breast cancer","volume":"25","author":"Tevaarwerk","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD003474.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/annonc\/mdh173","article-title":"Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomised, double-blind, placebo-controlled trial","volume":"15","author":"Tripathy","year":"2004","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD003474.pub4-BIB0107|cit107","first-page":"701","article-title":"Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases","volume":"88","author":"Tubiana-Hulin","year":"2001","journal-title":"Bulletin du Cancer"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0108|cit108","first-page":"73","article-title":"Effect of long-term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients","volume-title":"Recent Results in Cancer Research","volume":"116","author":"Cleton","year":"1989"},{"issue":"3","key":"10.1002\/14651858.CD003474.pub4-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1993.11.3.491","article-title":"Palliative pamidronate treatment in patients with bone metastases from breast cancer","volume":"11","author":"Holten-Vaerzantvoort","year":"1993","journal-title":"Journal of Clinical Oncology"},{"issue":"8566","key":"10.1002\/14651858.CD003474.pub4-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(87)92555-4","article-title":"Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment","volume":"330","author":"Holten-Verzantvoort","year":"1987","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD003474.pub4-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/0277-5379(91)90212-V","article-title":"The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer","volume":"27","author":"Holten-Verzantvoort","year":"1991","journal-title":"European Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD003474.pub4-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0959-8049(95)00564-1","article-title":"Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?","volume":"32A","author":"Holten-Verzantvoort","year":"1996","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0113|cit113","doi-asserted-by":"crossref","unstructured":"von Au A Milloth E Diel I Stefanovic S Hennigs A Wallwiener M Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority phase III trial OncoTargets and Therapy 2016 4173 80","DOI":"10.2147\/OTT.S103130"},{"issue":"5","key":"10.1002\/14651858.CD003474.pub4-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","article-title":"Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"},{"issue":"7","key":"10.1002\/14651858.CD003474.pub4-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD003474.pub4-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","article-title":"Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole","volume":"118","author":"Brufsky","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1002\/14651858.CD003474.pub4-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","article-title":"Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results","volume":"9","author":"Brufsky","year":"2009","journal-title":"Clinical Breast Cancer"},{"issue":"2","key":"10.1002\/14651858.CD003474.pub4-BIB0118|cit118","first-page":"e52","article-title":"Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial]","volume":"15","author":"Barrett-Lee","year":"2014","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD003474.pub4-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1470-2045(13)70539-4","article-title":"Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial","volume":"15","author":"Barrett-Lee","year":"2014","journal-title":"Lancet Oncology"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0120|cit120","first-page":"PD07","article-title":"Zoledronate versus ibandronate comparative evaluation (ZICE) trial-first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases","volume":"72","author":"Barrett-Lee","year":"2012","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0121|cit121","unstructured":"NCT00326820 Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer clinicaltrials.gov\/ct2\/show\/NCT00326820"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/1745-6215-14-325","article-title":"QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates","volume":"14","author":"Nelson","year":"2013","journal-title":"Trials"},{"issue":"2","key":"10.1002\/14651858.CD003474.pub4-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Annals of Oncology"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0124|cit124","first-page":"P2","article-title":"Influence of delayed zoledronic acid initiation on disease-free survival in postmenopausal women with endocrine receptor-positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO-FAST trial","volume":"71","author":"Coleman","year":"2011","journal-title":"Cancer Research"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0125|cit125","first-page":"S1","article-title":"Long-term survival outcomes among postmenopausal women with hormone receptor-positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5-year follow-up of ZO-FAST","volume":"71","author":"Boer","year":"2011","journal-title":"Cancer Research"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0126|cit126","first-page":"9","article-title":"Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number-needed-to-treat (NNT) analysis","volume":"7","author":"Boer","year":"2011","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD003474.pub4-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","article-title":"Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study","volume":"21","author":"Eidtmann","year":"2010","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD003474.pub4-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0129|cit129","unstructured":"NCT00375427 Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions clinicaltrials.gov\/ct2\/show\/NCT00375427"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0130|cit130","unstructured":"NCT00525759 Investigating the biological effects of the addition of zoledronic acid to pre-operative chemotherapy in breast cancer (ANZAC) clinicaltrials.gov\/ct2\/show\/NCT00525759"},{"issue":"10","key":"10.1002\/14651858.CD003474.pub4-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1158\/1078-0432.CCR-12-3235","article-title":"Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer--a randomized biomarker pilot study","volume":"19","author":"Winter","year":"2013","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"10.1002\/14651858.CD003474.pub4-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zolendronic acid reduces skeletal-related events in patients with osteolytic metastases: a double-blind, randomised dose-response study","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"issue":"3","key":"10.1002\/14651858.CD003474.pub4-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","article-title":"Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study","volume":"15","author":"Delmas","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD003474.pub4-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1210\/jc.2004-1444","article-title":"Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomised controlled trial","volume":"90","author":"Fuleihan","year":"2005","journal-title":"Journal of Endocrinology and Metabolism"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0135|cit135","first-page":"1050","article-title":"Prevention of bone loss in breast cancer survivors on aromatase inhibitors: results of the Rebbeca II trial","volume":"28","author":"Greenspan","year":"2013","journal-title":"Journal of Bone and Mineral Research"},{"issue":"16","key":"10.1002\/14651858.CD003474.pub4-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1200\/JCO.2007.15.2967","article-title":"Risedronate\u00a0prevents\u00a0bone\u00a0loss\u00a0in\u00a0breast\u00a0cancer\u00a0survivors:\u00a02-year,\u00a0randomized,\u00a0double-blind,\u00a0placebo-controlled clinical trial","volume":"26","author":"Greenspan","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD003474.pub4-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1200\/JCO.2008.19.1783","article-title":"Phase\u00a0III\u00a0randomized,\u00a0placebo-controlled,\u00a0double-blind\u00a0trial\u00a0of\u00a0risedronate\u00a0for the prevention\u00a0of\u00a0bone\u00a0loss\u00a0in\u00a0premenopausal women\u00a0undergoing\u00a0chemotherapy\u00a0for\u00a0primary\u00a0breast\u00a0cancer","volume":"27","author":"Hines","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD003474.pub4-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1023\/A:1012506426440","article-title":"Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease","volume":"12","author":"Jagdev","year":"2001","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD003474.pub4-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3892\/ol_00000044","article-title":"Adjuvant pamidronate therapy prevents the development of bone metastases in breast cancer patients with four or more positive nodes","volume":"1","author":"Kokufu","year":"2010","journal-title":"Oncology Letters"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10549-004-3722-5","article-title":"Clondronate treatment influences MMP-2 associated outcome in node positive breast cancer","volume":"90","author":"Leppa","year":"2005","journal-title":"Breast Cancer Research and Treatment"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0141|cit141","first-page":"P6","article-title":"Adding zoledronic acid to neo-adjuvant chemotherapy may improve the efficiency of chemotherapy in locally advanced breast cancer: results from the prospective randomized study NEOZOL","volume":"76","author":"Mathevet","year":"2016","journal-title":"Cancer Research"},{"issue":"3","key":"10.1002\/14651858.CD003474.pub4-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ejca.2009.12.003","article-title":"Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer","volume":"46","author":"McCloskey","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10549-014-2860-7","article-title":"Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: the ProBONE II study","volume":"144","author":"Hadji","year":"2014","journal-title":"Breast Cancer Research & Treatment"},{"issue":"4","key":"10.1002\/14651858.CD003474.pub4-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00198-013-2615-z","article-title":"Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study","volume":"25","author":"Hadji","year":"2014","journal-title":"Osteoporosis International"},{"issue":"1","key":"10.1002\/14651858.CD003474.pub4-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00198-014-2955-3","article-title":"Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy","volume":"26","author":"Kalder","year":"2015","journal-title":"Osteoporosis International"},{"issue":"2","key":"10.1002\/14651858.CD003474.pub4-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00223-004-0262-2","article-title":"Three-year\u00a0oral\u00a0clodronate\u00a0treatment\u00a0does not impair mineralization of newly formed bone-a histomorphometric study","volume":"77","author":"Saarto","year":"2005","journal-title":"Calcified Tissue International"},{"issue":"7","key":"10.1002\/14651858.CD003474.pub4-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/02841860410032885","article-title":"Ten-year follow-up of a randomised controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients","volume":"43","author":"Saarto","year":"2004","journal-title":"Acta Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"e12043","DOI":"10.1200\/JCO.2016.34.15_suppl.e12043","article-title":"BONADIUV trial: a single blind, randomized placebo controlled phase II study using oral ibandronate for osteopenic women receiving adjuvant aromatase inhibitors: final safety analysis","volume":"34","author":"Livi","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"TPS658","DOI":"10.1200\/jco.2014.32.15_suppl.tps658","article-title":"A single-blind, randomized, placebo-controlled phase II study to evaluate the impact of oral bisphosphonate treatment on bone mineral density in osteopenic women receiving adjuvant aromatase inhibitors: Interim analysis of \"BONADIUV\" trial","volume":"32","author":"Scotti","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"13","key":"10.1002\/14651858.CD003474.pub4-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S1470-2045(14)71035-6","article-title":"Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial","volume":"15","author":"Sestak","year":"2014","journal-title":"Lancet Oncology"},{"issue":"13","key":"10.1002\/14651858.CD003474.pub4-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"e587","DOI":"10.1016\/S1470-2045(14)71152-0","article-title":"Correction to Lancet Oncology 2014; 15: 1464","volume":"15","author":"Sestak","year":"2014","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003474.pub4-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0002-9343(83)90958-0","article-title":"Effects\u00a0of\u00a0dichloromethylene diphosphonate\u00a0in\u00a0women\u00a0with\u00a0breast\u00a0carcinoma\u00a0metastatic\u00a0to the\u00a0skeleton","volume":"74","author":"Siris","year":"1983","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0153|cit153","first-page":"2373","article-title":"Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment","volume":"37","author":"Vehmanen","year":"2001","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1023\/B:BREA.0000041624.00665.4e","article-title":"Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure","volume":"87","author":"Vehmanen","year":"2004","journal-title":"Breast Cancer Research and Treatment"},{"issue":"2","key":"10.1002\/14651858.CD003474.pub4-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","article-title":"Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions","volume":"42","author":"Weinfurt","year":"2004","journal-title":"Medical Care"},{"issue":"15 Suppl (May 2","key":"10.1002\/14651858.CD003474.pub4-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/jco.2012.30.15_suppl.511","article-title":"Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer","volume":"30","author":"Coleman","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0157|cit157","unstructured":"NCT00458796 Comparison of two schedules of zoledronic acid in treating patients with breast cancer that has spread to the bone clinicaltrials.gov\/ct2\/show\/NCT00458796"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0158|cit158","first-page":"P2","article-title":"Effects of de-escalated bisphosphonate therapy on bone turnover or metastasis markers and their correlation with risk of skeletal related events - a biomarker analysis in conjunction with the REFORM study","volume":"72","author":"Addison","year":"2012","journal-title":"Cancer Research"},{"issue":"5","key":"10.1002\/14651858.CD003474.pub4-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/COC.0b013e3182568f7a","article-title":"Randomized feasibility study of de-escalated (Every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer","volume":"36","author":"Amir","year":"2013","journal-title":"American Journal of Clinical Oncology"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0160|cit160","first-page":"P4","article-title":"Pilot randomized trial of de-escalated (q12 weekly) versus standard (q3-4 weekly) intravenous bisphosphonates in women with low-risk bone metastases from breast cancer","volume":"71","author":"Amir","year":"2011","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0161|cit161","first-page":"150","article-title":"A randomised, double-blind, placebo-controlled multicentre phase 3 study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-care)","volume":"7","author":"Bell","year":"2011","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0162|cit162","first-page":"OT1","article-title":"A phase 3 randomized, double-blind, placebo-controlled multicenter study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE)","volume":"71","author":"Goss","year":"2011","journal-title":"Cancer Research"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0163|cit163","first-page":"published onlin","article-title":"A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE)","volume":"29","author":"Goss","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0164|cit164","first-page":"Published onlin","article-title":"Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): an international, randomized, double-blind, placebo-controlled phase III clinical trial","volume":"30","author":"Goss","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"OT2","DOI":"10.1158\/0008-5472.SABCS13-OT2-6-02","article-title":"Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): a global, placebo-controlled, randomized, double-blind, phase 3 clinical trial","volume":"73","author":"Goss","year":"2013","journal-title":"Cancer Research"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0166|cit166","first-page":"published onlin","article-title":"Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): an international, placebo-controlled, randomized, double-blind phase III clinical trial","volume":"31","author":"Goss","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0167|cit167","first-page":"OT2","article-title":"Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): an international, randomized, double-blind, placebo-controlled phase 3 clinical trial","volume":"72","author":"Goss","year":"2012","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0168|cit168","unstructured":"NCT01077154 Study of denosumab as adjuvant treatment for women with high risk early breast cancer receiving neoadjuvant or adjuvant therapy (D-CARE) clinicaltrials.gov\/ct2\/show\/NCT01077154"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0169|cit169","first-page":"P5","article-title":"Zoledronic acid combined with adjuvant tamoxifen with or without ovarian function suppression in premenopausal early breast cancer patients","volume":"76","author":"El-Ibrashi","year":"2016","journal-title":"Cancer Research"},{"issue":"9 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0170|cit170","first-page":"P5","article-title":"The impact of skeletal-related events on pain interference in patients with advanced breast cancer and bone metastases","volume":"75","author":"Fallowfield","year":"2015","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2407-14-66","article-title":"FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients","volume":"14","author":"Fasching","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0172|cit172","unstructured":"NCT00412022 HOBOE: a phase 3 study of adjuvant triptorelin and tamoxifen, letrozole, or letrozole and zoledronic acid in premenopausal patients with breast cancer clinicaltrials.gov\/ct2\/show\/NCT00412022"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/annonc\/mdr600","article-title":"Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study","volume":"23","author":"Nuzzo","year":"2012","journal-title":"Annals of Oncology"},{"issue":"31 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/jco.2014.32.31_suppl.155","article-title":"A randomized, double-blind trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronate in patients with high-risk bone metastases from breast cancer (The Odyssey Study)","volume":"32","author":"Jacobs","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"10116","DOI":"10.1200\/JCO.2016.34.15_suppl.10116","article-title":"Efficacy and safety of denosumab from a phase III, randomized, active-controlled study compared with zoledronic acid in patients of Asian ancestry with bone metastases from solid tumors","volume":"34","author":"Jiang","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD003474.pub4-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"e0143643","DOI":"10.1371\/journal.pone.0143643","article-title":"Randomized controlled trial of zoledronic acid plus chemotherapy versus chemotherapy alone as neoadjuvant treatment of HER2-negative primary breast cancer (JONIE Study)","volume":"10","author":"Hasegawa","year":"2015","journal-title":"PLoS ONE"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0177|cit177","first-page":"PD3","article-title":"Disease-free survival and Ki67 analysis of a randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer (JONIE-1 study)","volume":"73","author":"Miura","year":"2013","journal-title":"Cancer Research"},{"issue":"9 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0178|cit178","first-page":"P6","article-title":"Exploring biomarkers of response to zoledronic acid in breast cancer from clinical trial result of neoadjuvant chemotherapy with zoledronic acid: JONIE-1 study","volume":"75","author":"Sangai","year":"2015","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0179|cit179","doi-asserted-by":"crossref","unstructured":"Sangai T Sato E Ishikawa T Kaise H Hasegawa Y Miura D Exploring immunomodulatory effects of zoledronic acid in breast cancer from clinical trial result of neoadjuvant chemotherapy with zoledronic acid: JONIE-1 study Cancer Research 2016 P4 09-25","DOI":"10.1158\/1538-7445.SABCS15-P4-09-25"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"TPS635","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS635","article-title":"Investigating denosumab as add-on neoadjuvant treatment for hormone receptor-negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules-2x2 factorial design (GeparX)","volume":"34","author":"Kummel","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0181|cit181","unstructured":"NCT00196859 Study in elderly patients with early breast cancer (ICE) clinicaltrials.gov\/ct2\/show\/NCT00196859"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0182|cit182","unstructured":"NCT00301886 Zoledronate or ibandronate in preventing bone problems in women with stage IV breast cancer that has spread to the bone clinicaltrials.gov\/ct2\/show\/NCT00301886"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0183|cit183","unstructured":"NCT00524849 Zometa and circulating vascular endothelial growth factor (VEGF) in breast cancer patients with bone metastasis clinicaltrials.gov\/ct2\/show\/NCT00524849"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0184|cit184","unstructured":"NCT01129336 Effect of zoledronic acid as anti-cancer treatment in metastatic breast cancer patients (Z-ACT 1) clinicaltrials.gov\/ct2\/show\/NCT01129336"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.breast.2015.10.005","article-title":"Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II\/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01)","volume":"25","author":"Charehbili","year":"2016","journal-title":"Breast"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0186|cit186","first-page":"P1","article-title":"Changes in circulating vitamin D levels as a predictor for pathological response to neoadjuvant chemotherapy (NAC) in breast cancer (BC): a Dutch breast cancer trialists group (BOOG) side-study","volume":"73","author":"Charehbili","year":"2013","journal-title":"Cancer Research"},{"issue":"5","key":"10.1002\/14651858.CD003474.pub4-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/annonc\/mdu102","article-title":"Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II\/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)","volume":"25","author":"Charehbili","year":"2014","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD003474.pub4-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.molonc.2015.02.001","article-title":"Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: results from the NEOZOTAC trial","volume":"9","author":"Dekker","year":"2015","journal-title":"Molecular Oncology"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0189|cit189","first-page":"P1","article-title":"The predictive value of tumor-stroma ratio for radiological and pathological response to neoadjuvant chemotherapy in breast cancer (BC): a Dutch breast cancer trialists group (BOOG) side-study","volume":"73","author":"Dekker","year":"2013","journal-title":"Cancer Research"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0190|cit190","first-page":"PD07","article-title":"NEO-ZOTAC: toxicity data of a phase III randomized trial with NEOadjuvant chemotherapy (TAC) with or without ZOledronic acid (ZA) for patients with HER2-negative large resectable or locally advanced breast cancer (BC)","volume":"72","author":"Ven","year":"2012","journal-title":"Cancer Research"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0191|cit191","first-page":"OT1","article-title":"NEO-ZOTAC: a phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative large resectable or locally advanced breast cancer","volume":"71","author":"Ven","year":"2011","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0192|cit192","unstructured":"NCT02051218 Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks clinicaltrials.gov\/ct2\/show\/NCT02051218"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0193|cit193","first-page":"published onlin","article-title":"Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: a noninferiority phase III trial (SAKK 96\/12, REDUSE)","volume":"32","author":"Templeton","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0194|cit194","first-page":"140","article-title":"Participation in the SUCCESS-A trial improves intensity and quality of care for patients with primary breast cancer","volume":"34","author":"Andergassen","year":"2013","journal-title":"Tumor Diagnostik und Therapie"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"11042","DOI":"10.1200\/jco.2013.31.15_suppl.11042","article-title":"Evaluation of prevalence, number, and temporal changes of circulating tumor cells as assessed after 2 and 5 years of follow-up in patients with early breast cancer in the SUCCESS A study","volume":"31","author":"Bauer","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0196|cit196","first-page":"S2","article-title":"Persistence of circulating tumor cells in high risk early breast cancer patients during follow-up care suggests poor prognosis-results from the adjuvant SUCCESS A trial","volume":"76","author":"Janni","year":"2016","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0197|cit197","unstructured":"NCT02181101 Simultaneous study of gemcitabine-docetaxel combination adjuvant treatment, as well as extended bisphosphonate and surveillance-trial SUCCESS-Trial clinicaltrials.gov\/ct2\/show\/NCT02181101"},{"issue":"3","key":"10.1002\/14651858.CD003474.pub4-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10549-014-2906-x","article-title":"A phase II multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events","volume":"144","author":"Addison","year":"2014","journal-title":"Breast Cancer Research and Treatment"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0199|cit199","first-page":"OT1","article-title":"A multicentre study assessing 12-weekly intravenous bisphosphonate therapy in women with low risk bone metastases from breast cancer - the TRIUMPH trial","volume":"71","author":"Bouganim","year":"2011","journal-title":"Cancer Research"},{"issue":"24 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0200|cit200","first-page":"P3","article-title":"Evaluating efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal related events. TRIUMPH: a pragmatic multicentre trial","volume":"72","author":"Bouganim","year":"2012","journal-title":"Cancer Research"},{"issue":"3","key":"10.1002\/14651858.CD003474.pub4-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10549-014-2906-x","article-title":"A phase II multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events","volume":"144","author":"Addison","year":"2014","journal-title":"Breast Cancer Research and Treatment"},{"issue":"5","key":"10.1002\/14651858.CD003474.pub4-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","article-title":"Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial","volume":"11","author":"Aft","year":"2010","journal-title":"Lancet Oncology"},{"issue":"4","key":"10.1002\/14651858.CD003474.pub4-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1214\/aos\/1176345976","article-title":"Cox's regression model for counting processes: a large sample study","volume":"10","author":"Andersen","year":"1982","journal-title":"Annals of Statistics"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0204|cit204","doi-asserted-by":"crossref","unstructured":"Poznak CHV Temin S Yee GC Janjan NA Barlow WE Biermann JS American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer Journal of Clinical Oncology 2011 1221 7","DOI":"10.1200\/JCO.2010.32.5209"},{"issue":"18","key":"10.1002\/14651858.CD003474.pub4-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.2016.70.7257","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Dhesy-Thind","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003474.pub4-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.1998.16.3.1218","article-title":"Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review","volume":"16","author":"Bloomfield","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD003474.pub4-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","article-title":"Current use of bisphosphonates in oncology","volume":"16","author":"Body","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0208|cit208","unstructured":"Body JJ Lichinitser MR Diehl I Schlosser K Pfarr E Cavalli F Double-blind placebo-controlled trial of intravenous ibandronate in breast cancer metastatic to bone Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago Chicago American Society of Clinical Oncology 1999 575a"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0305-7372(85)90008-8","article-title":"Bone metastases and breast cancer","volume":"12","author":"Coleman","year":"1985","journal-title":"Cancer Treatment Reviews"},{"issue":"1","key":"10.1002\/14651858.CD003474.pub4-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman","year":"1987","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0211|cit211","doi-asserted-by":"crossref","unstructured":"Coleman R Bundred N De Boer R Llombart A Campbell I Neven P Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST 32nd Annual San Antonio Breast Cancer Symposium; 2009 Dec 9-13; San Antonio San Antonio San Antonio Breast Cancer Symposium (SABCS) 2009","DOI":"10.1158\/0008-5472.SABCS-09-4082"},{"issue":"7","key":"10.1002\/14651858.CD003474.pub4-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","article-title":"The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer","volume":"102","author":"Coleman","year":"2010","journal-title":"British Journal of Cancer"},{"issue":"23","key":"10.1002\/14651858.CD003474.pub4-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.2000.18.23.3925","article-title":"Identifying breast cancer patients at high risk for bone metastases","volume":"18","author":"Colleoni","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD003474.pub4-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/jnci\/93.7.534","article-title":"Methodology for treatment evaluation in patients with cancer metastatic to bone","volume":"93","author":"Cook","year":"2001","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0215|cit215","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"12","key":"10.1002\/14651858.CD003474.pub4-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","article-title":"Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up","volume":"19","author":"Diel","year":"2008","journal-title":"Annals of Oncology"},{"issue":"10001","key":"10.1002\/14651858.CD003474.pub4-BIB0217|cit217","first-page":"1353","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD003474.pub4-BIB0218|cit218","first-page":"111","article-title":"Clodronate for osteolytic metastases due to breast cancer","volume":"42","author":"Elomaa","year":"1988","journal-title":"Biomedicine and Pharmacotherapy"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003474.pub4-BIB0219|cit219","first-page":"53","article-title":"Treatment of skeletal disease in breast cancer: a controlled clodronate trial","volume":"8","author":"Elomma","year":"1987","journal-title":"Bone"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0220|cit220","doi-asserted-by":"crossref","unstructured":"Coleman R Body JJ Aapro M Hadji P Herrstedt J Bone health in cancer patients: ESMO Clinical Practice Guidelines Annals of Oncology 2014 iii124 37","DOI":"10.1093\/annonc\/mdu103"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"E259","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"International Journal of Cancer"},{"issue":"9768","key":"10.1002\/14651858.CD003474.pub4-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0223|cit223","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"issue":"8","key":"10.1002\/14651858.CD003474.pub4-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1646::AID-CNCR14>3.0.CO;2-#","article-title":"Issue concerning the role of chemotherapy and hormonal therapy of bone metastases from breast cancer","volume":"80","author":"Harvey","year":"1997","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0226|cit226","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"13","key":"10.1002\/14651858.CD003474.pub4-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-03-0325","article-title":"Zoledronic acid inhibits visceral metastases in the 4T1\/luc mouse breast cancer model","volume":"10","author":"Hiraga","year":"2004","journal-title":"Clinical Cancer Research"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"LBA9500","DOI":"10.1200\/jco.2014.32.18_suppl.lba9500","article-title":"Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE-2 trial","volume":"32","author":"Hortobagyi","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003474.pub4-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/8756-3282(95)00194-I","article-title":"Bone and cancer: pathophysiology and treatment of metastases","volume":"17","author":"Kanis","year":"1995","journal-title":"Bone"},{"issue":"2","key":"10.1002\/14651858.CD003474.pub4-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10911-005-5399-8","article-title":"Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy","volume":"10","author":"Kozlow","year":"2005","journal-title":"Journal of Mammary Gland Biology and Neoplasia"},{"issue":"1","key":"10.1002\/14651858.CD003474.pub4-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1017\/S0266462305050154","article-title":"Meta-analysis when only the median survival times are known: a comparison with individual patient data results","volume":"21","author":"Michiels","year":"2005","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"7","key":"10.1002\/14651858.CD003474.pub4-BIB0232|cit232","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003474.pub4-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/8756-3282(91)90057-P","article-title":"Mechanisms of osteolytic bone destruction","volume":"12","author":"Mundy","year":"1991","journal-title":"Bone"},{"issue":"8","key":"10.1002\/14651858.CD003474.pub4-BIB0234|cit234","first-page":"1546","article-title":"Mechanisms of bone metastases","volume":"80","author":"Mundy","year":"1987","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0235|cit235","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"8","key":"10.1002\/14651858.CD003474.pub4-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z","article-title":"Overview of bisphosphonates","volume":"80","author":"Rogers","year":"1997","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD003474.pub4-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","article-title":"Bisphosphonates: from the laboratory to the clinic and back again","volume":"25","author":"Russell","year":"1999","journal-title":"Bone"},{"issue":"1","key":"10.1002\/14651858.CD003474.pub4-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","article-title":"Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5 year results of a randomised controlled study","volume":"19","author":"Saarto","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1002\/1097-0142(19861215)58:12<2589::AID-CNCR2820581206>3.0.CO;2-O","article-title":"Clinical course of breast cancer patients with osseous metastases treated with combination chemotherapy","volume":"58","author":"Scheid","year":"1986","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0240|cit240","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0241|cit241","unstructured":"Schunemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glaziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org."},{"key":"10.1002\/14651858.CD003474.pub4-BIB0242|cit242","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and \u2018Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0243|cit243","unstructured":"Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD003474.pub4-BIB0244|cit244","first-page":"published onlin","article-title":"Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: a noninferiority phase III trial (SAKK 96\/12, REDUSE)","volume":"32","author":"Templeton","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003474.pub4-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo-controlled trial","volume":"17","author":"Theriault","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"8566","key":"10.1002\/14651858.CD003474.pub4-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(87)92555-4","article-title":"Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment","volume":"330","author":"Holten-Verzantvoort","year":"1987","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD003474.pub4-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/0277-5379(91)90212-V","article-title":"The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer","volume":"27","author":"Holten-Verzantvoort","year":"1991","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003474.pub4-BIB0249|cit249","unstructured":"World Health Organization (WHO) World Cancer Report The International Agency for Research on Cancer 2003"},{"issue":"1","key":"10.1002\/14651858.CD003474.pub4-BIB0250|cit250","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003474","article-title":"Bisphosphonates for breast cancer","author":"Pavlakis","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD003474.pub4-BIB0251|cit251","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003474.pub2","article-title":"Bisphosphonates for breast cancer","author":"Pavlakis","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003474.pub4-BIB0252|cit252","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003474.pub3","article-title":"Bisphosphonates and other bone agents for breast cancer","author":"Matthew HF","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD003474.pub4\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T20:32:15Z","timestamp":1659731535000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003474.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Breast Cancer Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,10,30]]},"references-count":252,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003474.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,30]]}}}